This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ehrhardt, A. F.
Right arrow Articles by Moland, E. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ehrhardt, A. F.
Right arrow Articles by Moland, E. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 1999, p. 630-633, Vol. 43, No. 3
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Use of an Isogenic Escherichia coli Panel To Design Tests for Discrimination of beta -Lactamase Functional Groups of Enterobacteriaceae

Anton F. Ehrhardt,* Christine C. Sanders, and Ellen S. Moland

Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology, Creighton University School of Medicine, Omaha, Nebraska 68178

Received 21 May 1998/Returned for modification 1 September 1998/Accepted 14 December 1998

A study was designed to determine if an isogenic panel of Escherichia coli strains containing many different beta -lactamases could be used for the preliminary screening of a large number of beta -lactam agents to identify which might be most useful in the development of a definitive test for specific beta -lactamases found among the members of family Enterobacteriaceae. The susceptibilities of 46 strains, comprising the isogenic panel, to expanded-spectrum cephalosporins, cephamycins, and aztreonam were determined in the presence and absence of beta -lactamase inhibitors in broth microdilution tests. The results indicated that strains producing extended-spectrum beta -lactamases (ESBLs) could be distinguished from strains producing other Bush-Jacoby-Medeiros functional group 2 or group 1 beta -lactamases. For strains producing group 1 beta -lactamases, cefpodoxime and ceftazidime MICs were >= 4 µg/ml and addition of clavulanate did not reduce the MICs more than fourfold. For strains producing group 2 enzymes other than ESBLs, cefpodoxime and ceftazidime MICs were <= 2 µg/ml. With a single exception (ceftazidime for the strain producing SHV-3), among strains producing ESBLs, cefpodoxime and ceftazidime MICs were >= 4 µg/ml and addition of clavulanate reduced the MICs by more than eightfold. Cephamycins could also be used to discriminate between strains producing group 1 beta -lactamases and ESBLs, since only the former required cefotetan concentrations as high as 8 µg/ml or cefoxitin concentrations of >16 µg/ml for inhibition. Other cephalosporins provided some discrimination between the various beta -lactamase producers, although they were not as reliable as either cefpodoxime or ceftazidime. These results indicate the utility of an isogenic panel for identification of candidate drugs among many for further testing with clinical isolates of the family Enterobacteriaceae to determine the best agents for detection of specific beta -lactamases in this family.

* Corresponding author. Mailing address: Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178. Phone: (402) 280-1881. Fax: (402) 280-1225. E-mail: antone{at}creighton.edu.

Antimicrobial Agents and Chemotherapy, March 1999, p. 630-633, Vol. 43, No. 3
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Pitout, J. D. D., Gregson, D. B., Poirel, L., McClure, J.-A., Le, P., Church, D. L. (2005). Detection of Pseudomonas aeruginosa Producing Metallo-{beta}-Lactamases in a Large Centralized Laboratory. J. Clin. Microbiol. 43: 3129-3135 [Abstract] [Full Text]  
  • Pitout, J. D. D., Hossain, A., Hanson, N. D. (2004). Phenotypic and Molecular Detection of CTX-M-{beta}-Lactamases Produced by Escherichia coli and Klebsiella spp.. J. Clin. Microbiol. 42: 5715-5721 [Abstract] [Full Text]  
  • Sanders, C. C., Ehrhardt, A. F., Moland, E. S., Thomson, K. S., Zimmer, B., Roe, D. E. (2002). {beta}lasEN: Microdilution Panel for Identifying {beta}-Lactamases Present in Isolates of Enterobacteriaceae. J. Clin. Microbiol. 40: 123-127 [Abstract] [Full Text]  
  • Randegger, C. C., Keller, A., Irla, M., Wada, A., Hächler, H. (2000). Contribution of Natural Amino Acid Substitutions in SHV Extended-Spectrum beta -Lactamases to Resistance against Various beta -Lactams. Antimicrob. Agents Chemother. 44: 2759-2763 [Abstract] [Full Text]  
  • Thomson, K. S., Sanders, C. C., Moland, E. S. (1999). Use of Microdilution Panels with and without beta -Lactamase Inhibitors as a Phenotypic Test for beta -Lactamase Production among Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter freundii, and Serratia marcescens. Antimicrob. Agents Chemother. 43: 1393-1400 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»